Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.70 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14893135 | 0.88 | MTNR1A (0.74) | MTNR1AMTNR1BHPGDCNR1CA12 | |
| SCHEMBL10289223 | 0.85 | MTNR1A (0.70) | MTNR1AMTNR1BHPGDCNR1CA12 | |
| SCHEMBL14817540 | 0.85 | MTNR1A (0.70) | MTNR1AMTNR1BHPGDCNR1CA12 | |
| SCHEMBL2204065 | 0.84 | NPSR1 (0.64) | HPGDKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL11896371 | 0.83 | MTNR1A (0.77) | MTNR1AMTNR1BHPGDCNR1CA12 | |
| SCHEMBL1010724 | 0.83 | MTNR1A (1.00) | MTNR1AMTNR1BHPGDCNR1TAAR1 | |
| SCHEMBL10310315 | 0.81 | MTNR1A (0.65) | MTNR1AMTNR1BHPGDCNR1CA12 | |
| SCHEMBL13926593 | 0.81 | MTNR1A (0.65) | MTNR1AMTNR1BHPGDCNR1TAAR1 | |
| SCHEMBL2605740 | 0.81 | MTNR1A (0.65) | MTNR1AMTNR1BHPGDCNR1CA12 | |
| SCHEMBL14241869 | 0.80 | MTNR1A (0.72) | MTNR1AMTNR1BHPGDCNR1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426108-B1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC (CA) | 2016-08-10 | — | — | EP | disclosed |
| EP-2426108-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MethylGene Inc. (CA) | 2012-03-07 | — | — | EP | disclosed |
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | ERBB2, ABL1, FLT1 | MTNR1A 2688/4885MTNR1B 2424/4885HPGD 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.